Diagnoptics develops and markets non-invasive diagnostic technologies to assess cardiovascular risk and the risk of diabetes. The extensively validated AGE Reader enables a doctor to non-invasively assess the cardiovascular risk of their patients within 12 seconds. The technology is extensively validated in >200 scientific publications and is currently being marketed internationally.

---

Website: diagnoptics.com